The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback